Litcius/Paper detail

Intravitreal Anti–Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic

Sophie Billioti de Gage, Jérôme Drouin, David Desplas, François Cuenot, Rosemary Dray‐Spira, Alain Weill, Mahmoud Zureik

2020JAMA Ophthalmology34 citationsDOIOpen Access PDF

Abstract

This cohort study uses data from the French National Health Data System to assess the decline in the use of intravitreal anti–vascular endothelial growth factors before, during, and after pandemic-associated lockdown periods.

Topics & Concepts

MedicinePandemicCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus2019-20 coronavirus outbreakDiseaseCohortOphthalmologyVirologyInternal medicineInfectious disease (medical specialty)OutbreakRetinal and Optic ConditionsRetinal Diseases and TreatmentsCerebral Venous Sinus Thrombosis
Intravitreal Anti–Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic | Litcius